More tools:Markets·Screener·Research·Chat

NextCure, Inc. Common Stock (NXTC) Financial Statements

NextCure, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00BTH5162
XNAS · usd
8.07▼ 0.35 (-4.16%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value—
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt—
Trading Information
Previous Close8.42
Day's Range7.69 – 8.57
52-Week Range1.55 – 15.74
Volume42.9K
Avg Volume253.4K
Share Statistics
Shares Outstanding
Employees40
ExchangeXNAS
Listed2019-05-09
Share count as of July 31, 2026
Loading Income Statement…
Key questions about NextCure, Inc. Common Stock (NXTC)
What is NextCure, Inc. Common Stock's Market Cap?
NextCure, Inc. Common Stock's Market Cap is $36.9M, based on as-reported figures from SEC (XBRL) filings.
What is NextCure, Inc. Common Stock's Net Income (TTM)?
NextCure, Inc. Common Stock's Net Income (TTM) is -$42.7M, based on as-reported figures from SEC (XBRL) filings.
What is NextCure, Inc. Common Stock's EBITDA?
NextCure, Inc. Common Stock's EBITDA is -$41.7M, based on as-reported figures from SEC (XBRL) filings.
What is NextCure, Inc. Common Stock's Diluted EPS (TTM)?
NextCure, Inc. Common Stock's Diluted EPS (TTM) is -9.34, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development
General and administrative
Restructuring and asset impairment charges———
Total operating expenses
Loss from operations
Other income, net
Net loss
Basic (in dollars per share)
Diluted (in dollars per share)